USA flag logo/image

An Official Website of the United States Government

Enzymatic Pleurodesis for Malignant Pleural Effusions

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
75476
Program Year/Program:
2005 / SBIR
Agency Tracking Number:
CA112818
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
AERIS THERAPEUTICS, INC.
AERIS THERAPEUTICS, INC. 10K GILL ST WOBURN, MA 01801 0172
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2005
Title: Enzymatic Pleurodesis for Malignant Pleural Effusions
Agency: HHS
Contract: 1R43CA112818-01
Award Amount: $100,000.00
 

Abstract:

DESCRIPTION (provided by applicant): This Phase I SBIR application is presented by Aeris Therapeutics, Inc. of Woburn, MA. It will examine the feasibility of using a novel enzyme based-system to produce safe, clinically-effective pleurodesis for treatment of malignant pleural effusions. Preliminary data, summarized in this application, suggest that an enzymatic system has the potential for being safer, simpler, less expensive, and more effective than existing treatment strategies. Pleural symphysis, wherein the visceral and parietal pleural surfaces become "fused," is essential for achieving clinically effective pleurodesis. This is most effectively accomplished by surgical stripping of the parietal pleura, which is followed by adherence of the visceral surface to the inner chest wall during healing. Aeris' enzyme based pleurodesis system replicates the effects of surgical pleurectomy without requiring surgery, using a buffered solution of trypsin and collagenase that chemically strips away the parietal and visceral pleural surfaces, leading to pleural symphysis and elimination of pleural effusions. In preliminary studies conducted in healthy sheep, this approach produced safe and effective pleurodesis within 21 days of treatment without clinical toxicity, altered lung physiology, or histological injury to lung parenchyma or soft tissue of the chest wall. The current proposal will focus on: 1) optimizing enzyme concentrations in the formulation to maximize safety and effectiveness in vivo, and 2) comparing responses following enzymatic treatment to those following talc slurry, the current standard non-surgical treatment for malignant effusions in clinical practice.

Principal Investigator:

Larry W. Tsai
7819370110
LTASI@AERISTHERAPEUTICS.COM

Business Contact:


7819370110
Small Business Information at Submission:

Aeris Therapeutics, Inc.
Aeris Therapeutics, Inc. 10-A Roessler Rd Woburn, MA 01801

EIN/Tax ID: 043531052
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No